Esperion Therapeutics (ESPR) investor relations material

Strategic vision and financial outlook

• Vision 2040 aims for sustainable profitability by 2026 and at least five marketed products by 2040, leveraging internal development, business development, and global expansion.

• Focus on expanding the bempedoic acid franchise, building a diversified portfolio, and advancing next-generation ACLY inhibitors for rare and orphan diseases.

• Plans to leverage U.S. commercial infrastructure for acquisitions, co-promotions, in-licensing, and revenue-share partnerships.

• Strong financial position with preliminary cash of $168 million, 2023 U.S. net sales of $156–$160 million, and total revenue of $400–$408 million, reflecting 34% year-over-year growth in retail prescriptions.

• Operating expense guidance for 2026: R&D $40–$50 million, SG&A $170–$195 million, total OPEX $210–$245 million.

Commercial execution and market expansion

• U.S. commercial execution drove record growth, with 90% payer coverage in both commercial and Medicare segments and 45,000+ prescribing physicians.

• Expanded personal and digital promotion, targeting 40,000 physicians personally and 80,000 digitally, with 25% of digital-only contacts resulting in prescriptions.

• Direct-to-consumer campaigns via connected TV and non-branded websites generated millions of impressions and website visits.

• Global expansion includes recent launches in Japan, partnerships in Canada, Israel, Australia, and New Zealand, and approvals in 41 countries.

• Over 600,000 patients treated globally, with new launches in major markets and inclusion in European guidelines.

Product pipeline and R&D initiatives

• Bempedoic acid franchise expanded by CLEAR Outcomes data, new guidelines, and label updates, increasing total addressable market from 10 to 70 million patients.

• Oral triple combination therapy (NEXLIZET plus low-dose statins) targets LDL reductions of 65–71%, with launch expected in the second half of 2027.

• Next-generation ACLY pipeline leverages AI-driven compound screening, focusing on indications like primary sclerosing cholangitis (PSC), a $1 billion+ market opportunity.

• PSC program (ESP-2001) expects IND-enabling data by summer 2026 and aims to enter the clinic by late 2026.

• Business development targets immediately accretive, late-stage or approved assets in cardiometabolic, kidney, and rare endocrine diseases.